Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05468372

Amphotericin Versus Posaconazole for Pulmonary Mucormycosis

A Randomized Controlled Trial of Amphotericin B Versus Posaconazole for Treating Pulmonary Mucormycosis

Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Conditions Mucormycosis; Pulmonary (Etiology)

Interventions Liposomal Amphotericin B Posaconazole 600 mg followed by posaconazole 300 mg once daily

Updated 7 times since 2022 Last updated: Sep 26, 2024 Started: Jul 1, 2022 Primary completion: Dec 31, 2024 Completion: Jul 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05468372, this PHASE2 trial focuses on Mucormycosis; Pulmonary (Etiology) and remains actively recruiting participants. Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh, it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Oct 2024 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Apr 2024 — May 2024 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Dec 2023 — Apr 2024 [monthly]

Recruiting PHASE2
Sep 2022 — Dec 2023 [monthly]

Recruiting PHASE2

First recorded

Jul 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Post Graduate Institute of Medical Education and Research, Chandigarh

Data source: Post Graduate Institute of Medical Education and Research, Chandigarh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chandigarh, India